Strategic Transformation 2023
Editas Medicine is a Leader in the CRISPR-based Gene Editing
Medicine Field
Reni-cel is an investigational gene editing medicine
that is a potential "best in class" treatment for sickle
cell disease and beta thalassemia
Ongoing RUBY and EdiTHAL clinical trials.
Editas holds exclusive foundational IP for Cas9
and Cas12a for the prevention or treatment of
human disease
• Source of non-dilutive capital
o Recently granted sublicenses to Vertex
Pharmaceuticals and Vor Bio
editas
MEDICINE
Proprietary As Cas12a is a high fidelity and high
efficiency CRISPR nuclease
• Core expertise in guide RNA design and chemistry for
high precision editing
Longer-term focus on creating important medicines
based on in vivo gene editing
Scaled CMC
8.8
• Leadership team with a proven track record of drug
development and commercialization
3View entire presentation